Compass Pathways Confirms Full Phase IIb Enrollment and Mid-2027 Cash Runway
Compass Pathways’s Q1 2026 earnings call reported full enrollment in its COMP360 Phase IIb psilocybin therapy trial and initiation of a pivotal Phase III study. The company confirmed a cash runway extending into mid-2027 after securing additional R&D funding.
1. Q1 2026 Earnings Call Overview
During its Q1 2026 call, Compass Pathways outlined key operational and clinical developments for its COMP360 psilocybin program. Management emphasized the transition from Phase IIb to a pivotal Phase III trial.
2. Clinical Trial Progress
The company announced full patient enrollment in the COMP360 Phase IIb study targeting treatment-resistant depression. Initiation timelines for the Phase III trial were confirmed, highlighting regulatory engagement in both the US and EU.
3. Financial Position
Compass Pathways reaffirmed its cash runway into mid-2027, underpinned by recent R&D funding commitments. Management discussed cost-containment measures and partnership structures designed to extend financial visibility through key clinical milestones.